These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21288057)

  • 21. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
    Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
    Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study.
    Di Martino M; Agabiti N; Bauleo L; Kirchmayer U; Cascini S; Pistelli R; Colamesta V; Patorno E; Pinnarelli L; Fusco D; Perucci CA; Davoli M;
    COPD; 2014 Aug; 11(4):414-23. PubMed ID: 24090036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
    Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
    Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
    Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
    J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
    Friedman M; Menjoge SS; Anton SF; Kesten S
    Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease.
    Koumis T; Samuel S
    Clin Ther; 2005 Apr; 27(4):377-92. PubMed ID: 15922812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
    Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
    Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
    Somand H; Remington TL
    Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
    Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
    Schramm W; Haake D; Brandt A
    Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
    Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
    Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
    Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
    Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
    Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
    Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.